HUE032431T2 - BMP-6 antitestek - Google Patents
BMP-6 antitestek Download PDFInfo
- Publication number
- HUE032431T2 HUE032431T2 HUE13818045A HUE13818045A HUE032431T2 HU E032431 T2 HUE032431 T2 HU E032431T2 HU E13818045 A HUE13818045 A HU E13818045A HU E13818045 A HUE13818045 A HU E13818045A HU E032431 T2 HUE032431 T2 HU E032431T2
- Authority
- HU
- Hungary
- Prior art keywords
- seq
- antibody
- polypeptide
- ser
- bmp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
- BMF"< ' antitestek fzaöádábnl igénypmdpk:1. Lgy antitest vagy antigén-kötő tragmense. roci\ kötődik a kantán BMP-6-hoz. {!. sz. szekvencia), tneh tartalmaz egx könny« lánc variábilis régiót tj t'VR) es tgv ache? lare variábilis régiót (BCYR), ahol az LC'VR tartalmazza az LCDRi, LCDR.2. és L0DR3 iompknneotariu.st niegUaiátOö ? a g art, at - i'DR-ekk es a sk YR tartan aazza a Ut PRL IICDR2, és HCDR3 CDR-ekey ahol az LCDRI az RSSLN1YRNLA polípepUd C. sa. szekvencia), m LCÜR2 az AATNLAD polipeptid O. sa. szekvencia), az LCDR3 a OOIWUÎΑ1 I pohpcptid (4 sz, '»/Axrn.vah a Ht'BRi a UY II· I 's Y S MH polipepud à s/ szekvenciát. ;t BCDR2 az Y INF YNDOÎK Y NL N FKjG polîpeptîd (6. sz.. szekvencia) vagy ) IN F VN Rt s I KYSTN'F&AI t'L szekvencia) *>«lipeptid, es aBCDRà ta RFFUN.NMDI plipçpiid (S. sz::;ikefeycnc!8).
- 2. Az I . igénypont szerinti antitest vagy inigén~k§td ÄgMCnMs #töitäi l.€DRi az RSI|f|NIYRNLÂ poNpepüd (2, sá. szekvpí|ia)s az IÆSR1 az AATBLAD poipeptid (3. sz. szekvencia), az LCDR3 az QUI WGÎFLÎ poiipepUd (4. sz, szekvencia), a BODRI a ukU'lVí \MB pYipepud r »> szeUvnvvB a UCDRY az YINN) MXAkWl \l \D poiípeptid *6. szekvencia), es a BCDR3 az RFHiN W1IR pMipeptid (£, sz, |zelvcnciá|,
- 3. Az I. igénypont szerinti antitest vagy antigén-kötő fragmense, ahol az LCDÍli áss RSéiYvtYRNl Λ poiavpnd t.L sz szekxoneno. az I Dl)R2 az peltpepdd ΑΛΙΜ ADM szekvencia), az LCDR3 az QGiWGTPLI polipeptid (4, sz. szekvencia)., a HCDR1 a GYÏFTSYAMF! polipeptid (5. sz, szekvencia), a BCDR2 az YÍNPYNRGTKYNENI'KG poápep.A <v ' sr s Nx orvai ^alR PR) r R^TGN \MPI tvlipeptui tF sz. szekvencia).3. Az I. igénypont szerinti antitest vagy antigén-kötő fragntensr, mely egy i.CVR-t &s egy n \R ο I VisOM, «no) az U \ R .o\ vesOt\ müge tvoud, e?·« a *R'\ R t "0 sut s '1. sz. szekvenciáid poli pepiid. " N ; vm wT'U' V nc\t \ % > auigeod t o tto* ιοοή, ot 11 \ R a > s& szekvenemm polipeptid,. es a HCVR a 10, sz. szekvenciái« polipeptid. 6. Λ 4 -génxpom szerinti antitest vac> andgéU'kötö iragmensm az I.CVR a 9 az. szekvenciáid pohpeptid, éa λ Ik'VR a ' L v. smkseneutja pdspepísd. ” \z I \agx 4 tgenxpont szerion am aesg »neh .e> komon láncot 'Cicsogx tchc ’ kztcot Om pm&lnw, ahol a/ LC a Ik, sz. s/ekxendasu poUpepùd, es a UC a 1 * so szekxeneiàjtt vagy 14. SX, p!|ppid> 8, Λ ?. igénypont szerinti achtest- ahnt az 1 .€ a 12. sz. szekvenciája polipeptid, és a HC a O-sz. szekvenciàjû polipeptid. 9. A 7. igénypont sze-rmíi amitest. ahoi az LC a \2. sz szekvenciôiû polipeptid, es a NC a 14. sXi skékvenciáj « poh pepüd, Ht, Az 1 -, 4, vagy 7. igénypont szerinti antitest, mely két kömmt láncot és két nehéz láncot tartalmaz, ahol mindegyik köppyi lóé és mlndegylk ailéx lem ,íi' XZ SAktvTvU I p''h])t'pt«C H. Λ/ L< 4, vagy ? igénypont szer-nn «mtnest, mets »d könnyít láncot isMt^íkÉéz imiéot \tiuänu.x, ahoi nnmLv ik kooav: Luk a 1. s,. wkx emo aú po i vptsd és nnndegx 4 m in / lám, a s 4. sz. szekseneiaiàpoiipepîtd.
- 12- Gyógyászati készítmény, mois ep\ ' , 1 mens porno \ Lat moh „kv. a oom antuevw antigén-kötő fhtgmensét, és egy díbgfdlptö hptxiozot- higP^4:vagy::fig#l|tnyapit: tartalmaz, 13, te m. Igénypnésk: bármelyike szerinti antitest vagy amigért-köto fragment^ terápiában történő alkalmazásra.
- 14. Az 1-1 L igénypontok bármelyike szerinti iUÉMNHyg? tPÖg|pdkd$ tfogpggife xt-mzegerx.-eg kezelésében töoeno ilaltmi asm
- 15. Aaaîiilesf tàg^Âïillpákáié·.ink? 8 H.lgéov^illMtAlîf.^WlÂâÂ, aholii vërsguggnyaëg krónikus kaiogségköl szimmtê. finom u* .14- An aMiiest vsgy agigëü-kSté fxsgiMgnsè s 15. tgfugpoat sggrtei alkâknaaâsM* afeol.;«.: ironikus botugslgbő! Mlttill fÉM! Mumialo allémig es kmsnkgs velèlisiàgségbQ! s/.ámia?.-ó anémia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737859P | 2012-12-17 | 2012-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032431T2 true HUE032431T2 (hu) | 2017-09-28 |
Family
ID=49918813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13818045A HUE032431T2 (hu) | 2012-12-17 | 2013-12-05 | BMP-6 antitestek |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8795665B2 (hu) |
| EP (1) | EP2931748B1 (hu) |
| JP (1) | JP6033459B2 (hu) |
| KR (1) | KR20150083918A (hu) |
| CN (1) | CN104870473B (hu) |
| AP (1) | AP2015008600A0 (hu) |
| AR (1) | AR093620A1 (hu) |
| AU (1) | AU2013363548A1 (hu) |
| BR (1) | BR112015012708A2 (hu) |
| CA (1) | CA2892911C (hu) |
| CL (1) | CL2015001639A1 (hu) |
| CY (1) | CY1118254T1 (hu) |
| DK (1) | DK2931748T3 (hu) |
| EA (1) | EA201590918A1 (hu) |
| ES (1) | ES2608381T3 (hu) |
| HK (1) | HK1209763A1 (hu) |
| HR (1) | HRP20161587T1 (hu) |
| HU (1) | HUE032431T2 (hu) |
| IL (1) | IL239242A0 (hu) |
| LT (1) | LT2931748T (hu) |
| MA (1) | MA38161A1 (hu) |
| ME (1) | ME02515B (hu) |
| MX (1) | MX2015007831A (hu) |
| PE (1) | PE20151164A1 (hu) |
| PH (1) | PH12015501360A1 (hu) |
| PL (1) | PL2931748T3 (hu) |
| PT (1) | PT2931748T (hu) |
| RS (1) | RS55413B1 (hu) |
| SG (1) | SG11201504695QA (hu) |
| SI (1) | SI2931748T1 (hu) |
| TN (1) | TN2015000277A1 (hu) |
| TW (1) | TW201439118A (hu) |
| WO (1) | WO2014099391A1 (hu) |
| ZA (1) | ZA201504282B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| KR102492057B1 (ko) * | 2016-06-15 | 2023-01-26 | 노파르티스 아게 | 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법 |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| AU2020292246A1 (en) * | 2019-06-12 | 2022-01-27 | Regeneron Pharmaceuticals, Inc. | Human antibodies to bone morphogenetic protein 6 |
| JP2023520969A (ja) * | 2020-04-07 | 2023-05-23 | マブウェル セラピューティクス インコーポレイテッド | 抗ｔｍｐｒｓｓ６抗体及びその用途 |
| CN114075287B (zh) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002077006A1 (en) | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| US8318167B2 (en) * | 2008-11-13 | 2012-11-27 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation of BMP-6 |
| US20110070242A1 (en) * | 2009-09-01 | 2011-03-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for Diagnosing and Treating Iron Dysregulation |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
-
2013
- 2013-11-27 AR ARP130104361A patent/AR093620A1/es unknown
- 2013-12-02 TW TW102144085A patent/TW201439118A/zh unknown
- 2013-12-05 ES ES13818045.0T patent/ES2608381T3/es active Active
- 2013-12-05 AU AU2013363548A patent/AU2013363548A1/en not_active Abandoned
- 2013-12-05 PT PT138180450T patent/PT2931748T/pt unknown
- 2013-12-05 KR KR1020157015613A patent/KR20150083918A/ko active IP Right Grant
- 2013-12-05 PE PE2015001017A patent/PE20151164A1/es not_active Application Discontinuation
- 2013-12-05 MA MA38161A patent/MA38161A1/fr unknown
- 2013-12-05 DK DK13818045.0T patent/DK2931748T3/da active
- 2013-12-05 CN CN201380066174.1A patent/CN104870473B/zh not_active Expired - Fee Related
- 2013-12-05 EA EA201590918A patent/EA201590918A1/ru unknown
- 2013-12-05 CA CA2892911A patent/CA2892911C/en not_active Expired - Fee Related
- 2013-12-05 SI SI201330363A patent/SI2931748T1/sl unknown
- 2013-12-05 JP JP2015547414A patent/JP6033459B2/ja not_active Expired - Fee Related
- 2013-12-05 EP EP13818045.0A patent/EP2931748B1/en active Active
- 2013-12-05 LT LTEP13818045.0T patent/LT2931748T/lt unknown
- 2013-12-05 SG SG11201504695QA patent/SG11201504695QA/en unknown
- 2013-12-05 HU HUE13818045A patent/HUE032431T2/hu unknown
- 2013-12-05 US US14/097,335 patent/US8795665B2/en not_active Expired - Fee Related
- 2013-12-05 RS RS20160958A patent/RS55413B1/sr unknown
- 2013-12-05 BR BR112015012708A patent/BR112015012708A2/pt not_active IP Right Cessation
- 2013-12-05 PL PL13818045T patent/PL2931748T3/pl unknown
- 2013-12-05 WO PCT/US2013/073239 patent/WO2014099391A1/en active Application Filing
- 2013-12-05 AP AP2015008600A patent/AP2015008600A0/xx unknown
- 2013-12-05 ME MEP-2016-233A patent/ME02515B/me unknown
- 2013-12-05 MX MX2015007831A patent/MX2015007831A/es unknown
-
2014
- 2014-06-26 US US14/316,137 patent/US8980582B2/en not_active Expired - Fee Related
-
2015
- 2015-06-04 IL IL239242A patent/IL239242A0/en unknown
- 2015-06-12 ZA ZA2015/04282A patent/ZA201504282B/en unknown
- 2015-06-12 CL CL2015001639A patent/CL2015001639A1/es unknown
- 2015-06-16 PH PH12015501360A patent/PH12015501360A1/en unknown
- 2015-06-16 TN TNP2015000277A patent/TN2015000277A1/fr unknown
- 2015-10-23 HK HK15110455.0A patent/HK1209763A1/zh not_active IP Right Cessation
-
2016
- 2016-11-24 CY CY20161101225T patent/CY1118254T1/el unknown
- 2016-11-29 HR HRP20161587TT patent/HRP20161587T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE032431T2 (hu) | BMP-6 antitestek | |
| TW201525004A (zh) | 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之人類抗原結合蛋白 | |
| EP2032605A2 (en) | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY | |
| WO2016122996A1 (en) | Vegfa/ang2 compounds | |
| CA3032692A1 (en) | Combination antibody therapy for the treatment of neurodegenerative diseases | |
| CN117402244A (zh) | Btla激动剂抗体及其用途 | |
| JP2019510474A (ja) | トロンビン抗体、その抗原結合フラグメント及び医薬用途 | |
| US20230399390A1 (en) | Novel anti-nogo-a antibodies | |
| CN113840836B (zh) | 抗***生长因子抗体及其应用 | |
| KR20230004659A (ko) | 항-인간 신경 성장 인자 항체 | |
| JP2020524988A (ja) | 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用 | |
| AU2021390125A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
| JP2023537417A (ja) | アブドラリマブによる皮下抗Ｃ５ａＲアンタゴニスト治療レジメン |